Navigation Links
NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance
Date:12/2/2008

agreement with DSM and the importance of cost control in the current economic environment, NicOx has ended its present API supply agreement with Archimica. At the point of termination, Archimica had met all contract milestones and was in full compliance with the other terms of the contract.

Luca Mantovani, President & Business Unit Director at DSM Pharma Chemicals, declared: "We are happy to consolidate our relationship with NicOx through this agreement. Naproxcinod is an exciting compound and being part of its pre-launch and future commercialization plans is an interesting opportunity for DSM."

On November 24, NicOx announced that the third pivotal phase 3 study for naproxcinod in osteoarthritis of the hip had met all three co-primary efficacy endpoints. Following the positive results from the 301 and 302 studies in osteoarthritis of the knee, 303 represents the third pivotal phase 3 study for naproxcinod to achieve p<0.001 on all three co-primary efficacy endpoints. In addition, naproxcinod 750 mg bid showed the same gastrointestinal (GI) adverse event rate and a similar blood pressure profile to placebo in the 303 study.

This followed the announcement of positive results from a 118 patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the 111 study) on November 4, where naproxcinod showed a statistically significant reduction in systolic blood pressure of 3.8 mmHg (p=0.011) compared to naproxen over the whole study period. The filing of a New Drug Application (NDA) for naproxcinod with the U.S. Food and Drug Administration (FDA) is projected for mid-2009.

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more su
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

137

GOOD

Page: 1 2 3 4

Related biology technology :

1. NicOx Opens U.S. Headquarters in New Jersey
2. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
3. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Announces Departure of Damian Marron for CEO Position
6. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
7. NicOx Reports Results for the First Three Quarters of 2008
8. NicOx Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
9. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
10. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... needs and expertly narrows down the product choices to a manageable shortlist of ... down the list to models that fit best with the customer’s industry and ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader ... laboratory is to open in Manhattan, Kansas in early October, 2015. The location ... of research and development through collaboration with researchers from Kansas State University’s College ...
(Date:8/26/2015)... MO (PRWEB) , ... August 26, 2015 , ... ... it is increasing its investment in the development and manufacture of highly valued ... The company’s scientific team's extensive expertise with protein chemistry has led to ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... Product Line Extension Builds on Existing Brand Strength and Pediatric ... ... Focus, PLYMOUTH MEETING, Pa., Aug. 18 /Xinhua-PRNewswire-FirstCall/ ... that the Sunstone (Tangshan) Pharmaceutical Co., Ltd.,("Sunstone"), its wholly-owned subsidiary, ...
... Devices, SOUTH ORANGE, N.J., Aug. 18 The ... Capricci, 56, is a former public,school superintendent for the ... fisherman. After minor surgery a few years ago, he,experienced ... was out of work for nine weeks and wheelchair ...
... FOUR.OB) today announced it has appointed FBI Supervising Special Agent (Ret.) Dr. ... , ... NEW YORK (Business Wire EON) August 18, 2008 -- ... Federal Bureau of Investigation. Dr. Philip Hayden has spent years involved in ...
Cached Biology Technology:BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 2BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 3BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 4FDA Gets Knocked Out in Endotec, Inc. Ruling 2FDA Gets Knocked Out in Endotec, Inc. Ruling 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 2 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 4
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... its introduction, gene therapy still holds great promise as a ... human immunodeficiency syndrome (HIV). But scientists have yet to solve ... capable of delivering therapeutic payloads to specific cells. , ... USC Viterbi School of Engineering may be turning a corner. ...
... a self-assembly stage in which a powerful molecular motor must ... capsid). How it manages this intricate feat has been subject ... the capsid shell through a channel formed by a structure ... connector complex might feed the DNA into the capsid as ...
... new technique that reads the makeup of proteins to ... phosphate to proteins manufactured in human cells. , ... so-called phosphorylation events to lists compiled by others and ... PhosphoMotif Finder [ http://www.hprd.org/PhosphoMotif_finder ] - to ...
Cached Biology News:Can engineered immune cells stop AIDS? 2Can engineered immune cells stop AIDS? 3The connector rotation hypothesis? Phage do not pack their DNA by rotation 2Speeding 'fingertip' discovery -- 20 years of protein info in 1 place 2
Anti (porcine) Vitronectin...
... to work in collaboration with Pall Life ... filters in a variety of membrane chemistries. ... use on the Caliper TPWII, MultiDose, Prelude, ... for our Automation Certified Syringe Filters are ...
... BMP2 belongs to the transforming ... morphogenic protein induces bone formation. BMP2 ... autosomal dominant disease of fibrodysplasia (myositis) ... Synthetic peptide: PSDEVLSEFELRLLSM conjugated to KLH, ...
The Microseal 384 plate positioner ensures precise positioning of Microseal 384-well plates in the x-, y-, and z-dimensions, for accurate automated liquid handling....
Biology Products: